



Zynlonta | CD19

(loncastuximab tesirine-lpyl)
PBD dimer (SG3199) – cleavable linker
large B-cell lymphoma
0.15 mpk IV Q3W 2 cycles to 0.075 mpk Q3W
ADC Therapeutics (2021)




Trodelvy | Trop-2

(sacituzumab govitecan)
topoisomerase I inhibitor (SN38) – cleavable
metastatic triple-negative breast cancer
10 mg/kg IV on d1, d8 – 21d cycle
Immunomedics (acq. Gilead) (2020)




Padcev | Nectin-4

(enfortumab vedotin)
monomethyl auristatin E, cleavable linker
advanced or metastatic urothelial cancer
1.25 mpk IV over 30m Q1W, 3 wk of 28d cycle
Astellas/Seattle Genetics (2019)




Lumoxiti | CD22

(moxetumomab pasudotox)
Pseudomonas exotoxin, cleavable linker
relapsed or refractory hairy cell leukemia
0.04 mpk IV over 30m, d1, 3, 5 of 28d cycle, 6x
AstraZeneca (2018)




Kadcylla | HER2

(trastuzumab emtansine)
maytansinoid (DM1), non-cleavable linker
HER2-positive metastatic breast cancer
3.6 mg/kg IV over 90m, then 30m Q3W
Genentech, Roche (2013)




Mylotarg | CD33

(gemtuzumab ozogamicin)
calicheamycin, cleavable linker
relapsed acute myelogenous leukemia
3 mg/m² IV on days 1, 4, & 7
Pfizer/Wyeth (2000/2017)




Blenrep | BCMA

(belantamab mafodotin-blmf)
MMAF – non-cleavable linker
relapsed or refractory multiple myeloma
2.5 mg/kg IV over 30 min, Q3W
GlaxoSmithKline (2020)




Enhertu | HER2

(trastuzumab deruxtecan)
topoisomerase I inh. (deruxtecan) – cleavable
unresectable or metastatic HER2+ BC
5.4 mg/kg IV over 90 min, then 30 min, Q3W
AstraZeneca/Daiichi Sankyo (2019)




Polivy | CD79

(polatuzumab vedotin-piiq)
monomethyl auristatin E, cleavable linker
RR diffuse large B-cell lymphoma
1.8 mg/kg IV Q3W for 6 cycles
Genentech, Roche (2019)




Besponsa | CD22

(inotuzumab ozogamicin)
calicheamycin, cleavable linker
RR CD22+ B-cell precursor ALL
1.8 mpk IV Q1W 21d cycle, Q1W 3 wk/28d
Pfizer/Wyeth (2017)



Adcetris | CD30

(brentuximab vedotin)
monomethyl auristatin E, cleavable linker
replaced HL and relapsed sALCL
1.8 mg/kg IV over 30 mins Q3W
Seattle Genetics, Millennium/Takeda (2011)



Legend | Ab Target

non-proprietary name
warhead
indication
administration
sponsor and/or originator (year approved)

